Zealand Pharma, Coloplast, and Ambu have each lost more than 30% of their market value in the first half of the year, marking a significant underperformance among Denmark's largest listed companies.
The steep declines have triggered a reassessment of risk within the C25 index, with some investors choosing to exit positions rather than wait for a potential recovery.
The sell-off reflects broader pressures on the Danish equity market, where high-growth and healthcare names have faced particular scrutiny.
While the C25 index as a whole has shown resilience, these three constituents have dragged on performance, highlighting divergent trends within the blue-chip segment.
Investors are now weighing whether the drops represent a cyclical correction or a more fundamental shift in valuation.
The situation underscores the challenges of maintaining exposure to concentrated positions in a volatile market environment.